Since MYMD Pharma will eventually replace RCPIQ , I am going to submit what MYMD was saying about itself before they closed the curtain on their website.
"ABOUT US" "MYMD Pharma is a privately owned and funded clinical stage biotech company. MYMD has discovered, patent protected and is developing a novel, first in class drug (MYMD-1) to treat disease and aging at the root cause: immunometabolic dysfunction.
It is established that a balanced immunometabolic system is essential to maintaining healthy homeostasis; however, under stress or as we age, this complex system can commonly enter a state of dysfunction causing disease and aging. MYMD-1 is a novel drug platform that is being developed to treat a broad range of conditions, including autoimmune disease, cardiovascular disease, neurological disease and aging by addressing dysfunction of the immunometabolic system.
While the landscape of healthcare in the United States continues to change, at MYMD we continue to move science forward by arming researchers with creative solutions THAT CHALLENGE previous scientific understandings of immuno-metabolic systems in the body.
This year we have presented our investigational new drug (IND) application for our lead candidate, MYMD-1, to the US Food and Drug Administration. We are proceeding with a Phase 1 trial in healthy human volunteers for the treatment of Hashimoto's Thyroiditis. In addition to this Phase 1 trial, we are developing preclinical programs for other devastating conditions. We believe our unique approach could revolutionize treatment for many autoimmune disorders where the underlying pathology is driven or enhanced by the regulation of immuno-metabolic systems. These disorders often have a high unmet need for safe, effective therapies."
MORE TOMORROW
